Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT04339595
Other study ID # M-14745-44
Secondary ID 2019-003218-15
Status Terminated
Phase Phase 4
First received
Last updated
Start date January 29, 2020
Est. completion date July 31, 2020

Study information

Verified date November 2021
Source Almirall, S.A.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the psoriasis disease control over time in participants who had received Tildrakizumab for at least the last 5 years and have discontinued it and to describe blood and skin inflammatory biomarkers and its correlation disease relapse.


Recruitment information / eligibility

Status Terminated
Enrollment 47
Est. completion date July 31, 2020
Est. primary completion date July 31, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Participants provide signed written informed consent prior to perform any study-related activity - Participants has completed the long-term extension of the reSURFACE 2 study Exclusion Criteria: - Participants unable to comply with the requirements of the study - Participants who in the opinion of the investigator should not participate in the study

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Tildrakizumab
Participants who have participated and completed the long-term extension phase of the reSURFACE 2 study (NCT01729754) and 12 weeks after the last Tildrakizumab dose will be included in the present study. Participants will not receive any study medication during the present study. Participants will remain in the study for 96 weeks or until they initiate any systemic therapy for psoriasis (including phototherapy), whichever occurs first.

Locations

Country Name City State
Poland Site 0003 Lódz
Poland Site 0001 Wroclaw
Poland Site 0002 Wroclaw

Sponsors (1)

Lead Sponsor Collaborator
Almirall, S.A.

Country where clinical trial is conducted

Poland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants with Presence of Blood Inflammatory Biomarkers at Baseline Inflammatory biomarkers will be assessed using blood serum/plasma sample collected for local safety analysis. Baseline
Primary Number of Participants with Presence of Blood Inflammatory Biomarkers at Week 12 Inflammatory biomarkers will be assessed using blood serum/plasma sample collected for local safety analysis. Week 12
Primary Number of Participants with Presence of Blood Inflammatory Biomarkers at Week 24 Inflammatory biomarkers will be assessed using blood serum/plasma sample collected for local safety analysis. Week 24
Primary Number of Participants with Presence of Blood Inflammatory Biomarkers at Week 36 Inflammatory biomarkers will be assessed using blood serum/plasma sample collected for local safety analysis. Week 36
Primary Number of Participants with Presence of Blood Inflammatory Biomarkers at Week 48 Inflammatory biomarkers will be assessed using blood serum/plasma sample collected for local safety analysis. Week 48
Primary Number of Participants with Presence of Blood Inflammatory Biomarkers at Week 60 Inflammatory biomarkers will be assessed using blood serum/plasma sample collected for local safety analysis. Week 60
Primary Number of Participants with Presence of Blood Inflammatory Biomarkers at Week 72 Inflammatory biomarkers will be assessed using blood serum/plasma sample collected for local safety analysis. Week 72
Primary Number of Participants with Presence of Blood Inflammatory Biomarkers at Week 84 Inflammatory biomarkers will be assessed using blood serum/plasma sample collected for local safety analysis. Week 84
Primary Number of Participants with Presence of Blood Inflammatory Biomarkers at Week 96/End of Study (EOS) Inflammatory biomarkers will be assessed using blood serum/plasma sample collected for local safety analysis. Week 96/End of study (EOS)
Primary Number of Participants with Presence of Skin Inflammatory Biomarkers at Baseline Inflammatory biomarkers will be assessed using a small piece of 4 millimeter (mm) of skin biopsy sample collected at Baseline (stored in RNAlater solution). Baseline
Primary Number of Participants with Presence of Skin Inflammatory Biomarkers at Week 48 or End of Study (EOS) Inflammatory biomarkers will be assessed using a small piece of 4 millimeter (mm) of skin biopsy sample collected at Week 48 or until the date of initiation of any systemic therapy including phototherapy whichever comes first (EOS) (stored in RNAlater solution). up to Week 48
Primary Percentage of Participants Who Experienced Psoriasis Relapse Psoriasis Area and Severity Index (PASI) is a combination of the intensity of psoriasis, assessed by the erythema (reddening), induration (plaque thickness) and scaling on a scale range from 0 (no symptoms) to 4 (very marked), together with the percentage (%) of the area affected, rated on a scale from 0 (0%) to 6 (90-100%). PASI scoring is performed at four body areas, the head, arms, trunk, and legs. The total PASI score ranges from 0 (no psoriasis) to 72 (the most severe disease). Relapse is defined using the following thresholds: PASI greater than (>) 3 (participants who had a PASI lesser than or equal to [<=] 3 at baseline); PASI > 5 (participants who had a PASI <= 5 at baseline); DLQI > 5 (participants who had a DLQI <= 5 at baseline); Initiation of any topical drug/medication for psoriasis; Initiation of any systemic therapy for psoriasis (biologic or non-biologic). Baseline up to Week 96/ End of study (EOS)
Secondary Time to Psoriasis Relapse Time to relapse is defined as the time interval between the last administration of Tildrakizumab and the relapse of psoriasis in days. Baseline up to Week 96(EOS)
Secondary Absolute Psoriasis Area and Severity Index (PASI) Scores The PASI is a combination of the intensity of psoriasis, assessed by the erythema (reddening), induration (plaque thickness) and scaling on a scale range from 0 (no symptoms) to 4 (very marked), together with the percentage (%) of the area affected, rated on a scale from 0 (0%) to 6 (90-100%). PASI scoring is performed at four body areas, the head, arms, trunk, and legs. The total PASI score ranges from 0 (no psoriasis) to 72 (the most severe disease). Baseline, Weeks 12, 24, 36, 48, 60, 72, 84 and Week 96/ End of study (EOS)
Secondary Change from Baseline in Absolute Psoriasis Area and Severity Index (PASI) Scores The PASI is a combination of the intensity of psoriasis, assessed by the erythema (reddening), induration (plaque thickness) and scaling on a scale range from 0 (no symptoms) to 4 (very marked), together with the percentage (%) of the area affected, rated on a scale from 0 (0%) to 6 (90-100%). PASI scoring is performed at four body areas, the head, arms, trunk, and legs. The total PASI score ranges from 0 (no psoriasis) to 72 (the most severe disease). Change from baseline will be calculated by subtracting post-dose value from baseline value. Baseline, Weeks 12, 24, 36, 48, 60, 72, 84 and Week 96/ End of study (EOS)
Secondary Absolute Body Surface Area (BSA) Scores The BSA is a numerical score used to measure the total area of the body affected by psoriasis. The palm method will be applied: the participant's palm, including the five digits is used as a reference (representing approximately 1% of the total body surface area) and is used to repeatedly cover the lesions on the body. The investigator totals the number of palms required and then estimates the percentage (%) in each of the four body regions: head (including scalp) and neck (10%); upper extremities (20%); trunk (30%); and lower extremities (40%). Baseline, Weeks 12, 24, 36, 48, 60, 72, 84 and Week 96/ End of study (EOS)
Secondary Change from Baseline in Absolute Body Surface Area (BSA) Scores The BSA is a numerical score used to measure the total area of the body affected by psoriasis. The palm method will be applied: the participant's palm, including the five digits is used as a reference (representing approximately 1% of the total body surface area) and is used to repeatedly cover the lesions on the body. The investigator totals the number of palms required and then estimates the percentage (%) in each of the four body regions: head (including scalp) and neck (10%); upper extremities (20%); trunk (30%); and lower extremities (40%). Change from baseline will be calculated by subtracting post-dose value from baseline value. Baseline, Weeks 12, 24, 36, 48, 60, 72, 84 and Week 96/ End of study (EOS)
Secondary Absolute Dermatology Quality of Life Index (DLQI) Scores DLQI is a questionnaire to evaluate the impact on participant's quality of life due to psoriasis. It is composed of 10 items related to symptoms, feelings, daily activities, leisure, working or studying activities, personal relationships and opinions about dermatological treatment. Each item is scored from 0 (not affected at all) to 3 (very much affected). The DLQI score is the sum of the 10 individual question scores and ranges from 0 (no effect at all on participant's life) to 30 (extremely large effect on participant's life), with lower scores indicating better quality of life. Baseline, Weeks 12, 24, 36, 48, 60, 72, 84 and Week 96/ End of study (EOS)
Secondary Absolute Dermatology Quality of Life Index Scoring Modification (DLQI-R) Scores The DLQI-R is a scoring modification for the DLQI to better evaluate not relevant responses on the DLQI that could lead to underestimation of the impact on quality of life. DLQI-R is a scoring modification involves multiplying the original DLQI score by a conversion factor that increases with the number of not relevant responses. Baseline, Weeks 12, 24, 36, 48, 60, 72, 84 and Week 96/ End of study (EOS)
Secondary Change from Baseline in Absolute Dermatology Quality of Life Index (DLQI) Scores DLQI is a questionnaire to evaluate the impact on participant's quality of life due to psoriasis. It is composed of 10 items related to symptoms, feelings, daily activities, leisure, working/studying activities, personal relationships & opinions about dermatological treatment. Each item is scored from 0 (not affected at all) to 3 (very much affected). The DLQI score is the sum of the 10 individual question scores & ranges from 0 (no effect at all on participant's life) to 30 (extremely large effect on participant's life), with lower scores indicating better quality of life. Change from baseline will be calculated by subtracting post-dose value from baseline value. Baseline, Weeks 12, 24, 36, 48, 60, 72, 84 and Week 96/ End of study (EOS)
Secondary Change from Baseline in Absolute Dermatology Quality of Life Index Scoring Modification (DLQI-R) Scores DLQI-R is a scoring modification for the DLQI to better evaluate not relevant responses on the DLQI that could lead to underestimation of the impact on quality of life. DLQI-R, a scoring modification involves multiplying the original DLQI score by a conversion factor that increases with the number of not relevant responses. Change from baseline will be calculated by subtracting post-dose value from baseline value. Baseline, Weeks 12, 24, 36, 48, 60, 72, 84 and Week 96/ End of study (EOS)
Secondary Absolute Physician's Global Assessment (PGA) Scores The PGA is used to assess the overall severity of the psoriasis lesions at the time of evaluation. Overall lesions will be graded for erythema, induration, and scale based on 6-point scale ranging from 0 (clear) to 5 (severe). The sum of 3 scales will be divided by 3 to obtain final PGA score. Baseline, Weeks 12, 24, 36, 48, 60, 72, 84 and Week 96/ End of study (EOS)
Secondary Change from Baseline in Absolute Physician Global Assessment (PGA) Scores The PGA is used to assess the overall severity of the psoriasis lesions at the time of evaluation. Overall lesions will be graded for erythema, induration, and scale based on 6-point scale ranging from 0 (clear) to 5 (severe). The sum of 3 scales will be divided by 3 to obtain final PGA score. Change from baseline will be calculated by subtracting post-dose value from baseline value. Baseline, Weeks 12, 24, 36, 48, 60, 72, 84 and Week 96/ End of study (EOS)
Secondary Absolute Nail Physician Global Assessment (nPGA) Scores The nPGA is a 5-point scale ranging from 0 (clear) to 4 (severe), where higher score indicates severe nail psoriasis lesions. Only in participants with nail involvement the nPGA assessment will be performed. Baseline, Weeks 12, 24, 36, 48, 60, 72, 84 and Week 96/ End of study (EOS)
Secondary Change from Baseline in Absolute Nail Physician Global Assessment (nPGA) Scores The nPGA is a 5-point scale ranging from 0 (clear) to 4 (severe), where higher score indicates severe nail psoriasis lesions. Only in participants with nail involvement the nPGA assessment will be performed. Change from baseline will be calculated by subtracting post-dose value from baseline value. Baseline, Weeks 12, 24, 36, 48, 60, 72, 84 and Week 96/ End of study (EOS)
Secondary Absolute Scalp Physician Global Assessment (scPGA) Scores The scPGA score is used to assess the average severity of scalp psoriasis lesions. The scPGA is also 5-point scale ranging from 0 (clear) to 4 (severe), where higher score indicates severe scalp psoriasis lesions. Only in participants with scalp involvement, the scPGA assessment will be performed. Baseline, Weeks 12, 24, 36, 48, 60, 72, 84 and Week 96/ End of study (EOS)
Secondary Change from Baseline in Absolute Scalp Physician Global Assessment (scPGA) Scores The scPGA score is used to assess the average severity of scalp psoriasis lesions. The scPGA is also 5-point scale ranging from 0 (clear) to 4 (severe), where higher score indicates severe scalp psoriasis lesions. Only in participants with scalp involvement, the scPGA assessment will be performed. Change from baseline will be calculated by subtracting post-dose value from baseline value. Baseline, Weeks 12, 24, 36, 48, 60, 72, 84 and Week 96/ End of study (EOS)
Secondary Absolute Pain-Numeric Rating Scale (Pain-NRS) and Pruritus-Numeric Rating Scale (Pruritus-NRS) Scores Both Pain-NRS and Pruritus-NRS are a unidimensional segmented numeric version of the visual analog scale in which a respondent selects a whole number (0-10 integers) that best reflects the intensity of pain or pruritus. The 11-point numeric scale of NRS ranges from 0 to 10, describing pain severity extremes scale 0 (no pain) to 10 (worst imaginable pain) and pruritus-severity extremes scale 0 (no pruritis) to 10 (worst imaginable pruritus), where higher scores indicates worse pain and pruritus. Baseline, Weeks 12, 24, 36, 48, 60, 72, 84 and Week 96/ End of study (EOS)
Secondary Change from Baseline in Absolute Pain- and Pruritus-Numeric Rating Scale (NRS) Scores Both Pain-NRS and Pruritus-NRS are a unidimensional segmented numeric version of the visual analog scale in which a respondent selects a whole number (0-10 integers) that best reflects the intensity of pain or pruritus. The 11-point numeric scale of NRS ranges from 0 to 10, describing pain severity extremes scale 0 (no pain) to 10 (worst imaginable pain) and pruritus-severity extremes scale 0 (no pruritis) to 10 (worst imaginable pruritus), where higher scores indicates worse pain and pruritus. Change from baseline will be calculated by subtracting post-dose value from baseline value. Baseline, Weeks 12, 24, 36, 48, 60, 72, 84 and Week 96/ End of study (EOS)
Secondary Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) An AE is any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An SAE is any untoward medical occurrence that at any dose: results in death, or is life threatening, or requires in participant hospitalization or prolongation of existing hospitalization, or results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is any other medically important event. Baseline up to Week 96/ End of study (EOS)
Secondary Number of Participants with Clinically Significant Abnormalities in Physical Examination Physical Examination includes measuring height, weight, body mass index, waist circumference (cm), and waist hip ratio. Baseline up to Week 96/ End of study (EOS)
Secondary Number of Participants with Clinically Significant Change from Baseline in Vital Signs Following vital signs with clinically significant observation will be measured as safety variables: diastolic and systolic blood pressure, heart rate, respiratory rate and body temperature. Change from baseline will be calculated by subtracting post-dose value from baseline value. Baseline up to Week 96/ End of study (EOS)
Secondary Number of Participants with Clinically Significant Change from Baseline in Laboratory Parameters Clinically Significant hematology and biochemical parameters will be assessed. Change from baseline will be calculated by subtracting post-dose value from baseline value. Baseline up to Week 96/ End of study (EOS)
See also
  Status Clinical Trial Phase
Completed NCT01194219 - Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis Phase 3
Recruiting NCT06030076 - A Study to Assess the Effects of Switching From a Biologic Treatment to Tildrakizumab Using Patient-reported Outcomes in Adult Participants With Moderate to Severe Plaque Psoriasis
Completed NCT04263610 - Efficacy and Safety of Tildrakizumab in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Who Are Non-Responders to Dimethyl Fumarate Therapy Phase 4
Completed NCT02601469 - Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Plaque Psoriasis Phase 2
Completed NCT05600036 - A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Plaque Psoriasis Phase 2
Completed NCT05375955 - A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis. Phase 2
Completed NCT03614078 - A Study of PRCL-02 in Moderate to Severe Chronic Plaque Psoriasis Phase 2
Not yet recruiting NCT05036889 - A 16-week Randomized Evaluation of the Impact of Mind.Px Application on Response to Biologic Treatment in Patients Suffering From Plaque Psoriasis Through Clinical Utility and Health Outcomes. N/A
Completed NCT04603027 - A Phase 2 Study Investigating the Effect of EDP1815 in the Treatment of Mild to Moderate Plaque Psoriasis Phase 2
Completed NCT03638258 - The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis Phase 2
Completed NCT02881346 - Efficacy and Tolerability of Enstilar® in Daily Practice
Recruiting NCT02611349 - Study to Evaluate the Long-Term Safety of IDP-118 Lotion in the Treatment of Plaque Psoriasis Phase 3
Completed NCT02251678 - Evaluate the Effect of Elimune Capsules Phase 1
Completed NCT01987843 - Dose-finding Study of MT-1303 in Subjects With Moderate to Severe Chronic Plaque Psoriasis Phase 2
Terminated NCT01708629 - Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects Phase 3
Withdrawn NCT00747032 - To Demonstrate the Superior Efficacy of NYC 0462 Ointment Over That of the Placebo in the Treatment of Plaque Psoriasis Phase 3
Completed NCT01230138 - Pivotal Efficacy and Safety Registration Trial of FP187 in Moderate to Severe Plaque Psoriasis Phase 2
Completed NCT00581100 - Effects of Etanercept on Nail Psoriasis and Plaque Psoriasis Phase 4
Suspended NCT01228656 - Effectiveness of Association Mometasone Furoate 0.1% and Salicylic Acid 5% Compared With Mometasone Furoate Phase 2
Completed NCT00540618 - A Phase II Study of MEDI-507, Administered by Injection to Adults With Psoriasis Phase 2